Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: removal from study Clear all
Completed Early Phase 1 Interventional Results available

Examining Bioactivity of PVSRIPO in Invasive Breast Cancer

NCT03564782
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
PVSRIPO
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 30, 2026, 4:41 PM EDT
Not yet recruiting Not applicable Interventional

Peri-procedural Weighted Blanket Use for ECT

NCT07900646
View directory record Official record
Conditions
Post-ect Agitation, Post-ictal Agitation
Interventions
Weighted blanket, Usual Care Group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431
View directory record Official record
Conditions
Melanoma
Interventions
Poly ICLC, leukapheresis
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 30, 2026, 4:41 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

NCT06072586
View directory record Official record
Conditions
High Grade Glioma, Glioblastoma
Interventions
BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chandler, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

NCT03005054
View directory record Official record
Conditions
Trauma-related Wound, Burns, Skin Wound
Interventions
StrataGraft Skin Tissue, Autograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Fort Sam Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 30, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screening Strategies Among High-risk Populations for Anal Cancer

NCT06628570
View directory record Official record
Conditions
Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Interventions
HRA + Biopsy, Anal Cytology, Genotyping of anal hrHPV infection, CINtec®PLUS
Diagnostic Test
Lead sponsor
Lisa Flowers
Other
Eligibility
30 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

NCT01227434
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 30, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

NCT05753748
View directory record Official record
Conditions
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Endoscopic Eradication Therapy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects

NCT00426244
View directory record Official record
Conditions
Low Back Pain, Pregnancy
Interventions
Osteopathic Manipulative Treatment, Placebo Ultrasound
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 30, 2026, 4:41 PM EDT
Withdrawn Phase 2 Interventional

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

NCT02850874
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions
Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

NCT00256308
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720
View directory record Official record
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Completed No phase listed Observational

Systemic Symptoms: Biospecimen Analysis Study

NCT04255810
View directory record Official record
Conditions
Women With Breast Implants With and Without Self-reported Systemic Symptoms, Women Undergoing an Elective Mastopexy (Breast Lift) or Small Reduction
Interventions
Surgical collection of biospecimens
Procedure
Lead sponsor
Glicksman, Caroline, M.D.
Individual
Eligibility
30 Years to 65 Years · Female only
Enrollment
150 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sea Girt, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

NCT01655407
View directory record Official record
Conditions
Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
Interventions
Autologous Engineered Skin Substitute, Split-Thickness Autograft (AG)
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Pheonix, Arizona • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

NCT01192763
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 30, 2026, 4:41 PM EDT
Recruiting Phase 3 Interventional

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Completed No phase listed Observational

Impact of Obesity on Clinical Outcomes in Patients Receiving Acyclovir for HSV Encephalitis"

NCT05127395
View directory record Official record
Conditions
HSV Encephalitis
Interventions
To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

NCT01967537
View directory record Official record
Conditions
Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
Interventions
68Gallium DOTATATE, Radio-guided surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years to 99 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 30, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Dental Plaque Removal Study

NCT01559987
View directory record Official record
Conditions
Gingivitis, Gum Disease
Interventions
Manual Toothbrush only, MTB + Waterpik Ultra Water Flosser 'High', MTB + Floss (MTB+Floss)
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 4:41 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

NCT07043608
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
Drug · Radiation · Procedure
Lead sponsor
Kelly Fitzgerald, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Filter During CPET on WOB and Aerosol Particle Concentrations

NCT04526925
View directory record Official record
Conditions
Transmission, Patient-Professional
Interventions
Respiratory filter in-line placed with the standard mouthpiece, Standard mouthpiece
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 30, 2026, 4:41 PM EDT